info@seagull-health.com
SeagullHealth
search
Canakinumab(ILARIS)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Canakinumab(ILARIS) Instructions:Uses,Dosage, Side Effects
ILARIS® is a recombinant human monoclonal IgG1/κ antibody that selectively neutralizes interleukin-1β (IL-1β), a proinflammatory cytokine central to innate immune dysregulation. By binding IL-1β, it inhibits interaction with IL-1 receptors, thereby attenuating inflammation. ILARIS does not cross-react with IL-1α or IL-1 receptor antagonist (IL-1ra). It is approved for autoinflammatory syndromes driven by excessive IL-1β activity, including CAPS, TRAPS, HIDS/MKD, FMF, Still’s disease, and acute gout flares refractory to conventional therapies.
ILARIS is supplied as a 150 mg/mL sterile solution for subcutaneous injection in single-dose vials. Dosing frequency varies by indication: every 8 weeks for CAPS, every 4 weeks for TRAPS/HIDS/MKD/FMF/Still’s disease, and as a single dose for gout flares (minimum 12-week interval between doses). Contraindications include hypersensitivity to canakinumab or excipients. Warnings emphasize serious infections (e.g., tuberculosis reactivation, opportunistic pathogens), hypersensitivity reactions (including DRESS), and avoidance of live vaccines. Pre-treatment screening for latent infections and close monitoring during therapy are critical.
ILARIS® is indicated for:
1.Periodic Fever Syndromes:
Cryopyrin-Associated Periodic Syndromes (CAPS): Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS) in adults and pediatric patients ≥4 years.Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS).
Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD).
Familial Mediterranean Fever (FMF).
2.Still's Disease:
Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients ≥2 years.
3.Gout Flares:
Symptomatic treatment in adults with contraindications/intolerance to NSAIDs, colchicine, or repeated corticosteroids.
General Instructions:
Administer subcutaneously. Avoid injection into scar tissue.
Preparation: Use 18-gauge needle to withdraw; inject with 27-gauge needle.
Dosing by Indication:
CAPS:
>40 kg: 150 mg every 8 weeks.
15–40 kg: 2 mg/kg every 8 weeks (may increase to 3 mg/kg if inadequate response).
TRAPS, HIDS/MKD, FMF:
>40 kg: 150 mg every 4 weeks (may increase to 300 mg).
≤40 kg: 2 mg/kg every 4 weeks (may increase to 4 mg/kg).
Still’s Disease (AOSD/SJIA):
≥7.5 kg: 4 mg/kg (max 300 mg) every 4 weeks.
Gout Flares:
150 mg as a single dose. Re-treatment only after ≥12 weeks.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
